AKBA
Akebia Ther
–
Index: NASDAQ; Sector: Healthcare; Industry: Biotechnology & Drugs;
Marketcap: 342.08M; Volume: 1.06M; AvgVol 3m: 4.77M; Beta: 1.65;
Cost estimate:
P/E: –; EPS: -3.01; EPS growth quarter/prev quarter: -161.00%;
EPS growth this year: 4.50%; EPS growth past 5 years: 21.70%;
EPS ttm: -3.01;
P/S: 1.14; P/B: 1.00; P/Cashflow: 1.32; P/FCF: ;
Sales: 340.16M; Sales growth quarter/prev quarter: -10.60%; Sales growth past 5 years: ;
Profitability:
Gross Margin: 61.70%; Profit Margin: ; Operating Margin: ;
ROA – return on assets: -49.80%; ROE – return on equity: -94.70%; LT Debt/Equity: 0.21; Total Debt/Equity: 0.00;
Dividend: –; Dividend Yield (%): –;
Insider Ownership: 0.30%; Insider Transactions:-4.45%;
Institutional Ownership: 80.20%; Institutional Transactions: 19.53%;
Data update: 07.10.2020.